{"id":"morphine-6-glucuronide","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Sedation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Morphine 6-glucuronide (M6G) is formed through hepatic glucuronidation of morphine and acts as a mu-opioid receptor agonist. It crosses the blood-brain barrier and produces potent analgesic effects, potentially with a more favorable side effect profile than morphine itself. M6G accumulates in renal impairment, making it a consideration in pain management across different patient populations.","oneSentence":"Morphine 6-glucuronide is an active metabolite of morphine that binds to opioid receptors in the central nervous system to produce analgesia and other opioid effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:07.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute and chronic pain management"},{"name":"Postoperative pain"}]},"trialDetails":[{"nctId":"NCT01082471","phase":"PHASE3","title":"An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours","status":"COMPLETED","sponsor":"Paion UK Ltd.","startDate":"2005-11","conditions":"Postoperative Pain","enrollment":517},{"nctId":"NCT03035578","phase":"PHASE1, PHASE2","title":"Development of a Morphine Pharmacokinetic and Pharmacodynamic Model for the Neonatal Population","status":"WITHDRAWN","sponsor":"The Hospital for Sick Children","startDate":"2017-12-01","conditions":"Pain, Drug Effect","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"TOXICITY TO VARIOUS AGENTS"}],"_approvalHistory":[],"publicationCount":671,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Morphine 6-glucuronide","genericName":"Morphine 6-glucuronide","companyName":"Paion UK Ltd.","companyId":"paion-uk-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Morphine 6-glucuronide is an active metabolite of morphine that binds to opioid receptors in the central nervous system to produce analgesia and other opioid effects. Used for Acute and chronic pain management, Postoperative pain.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}